SolasCure publishes Phase IIa clinical trial data for Aurase Wound Gel, validating safety and proof-of-concept, derived from medical maggots for wound healing.

SolasCure, a biotech company developing novel wound care treatments, announces the publication of Phase IIa clinical trial data for its Aurase Wound Gel in the International Wound Journal, validating its safety and proof-of-concept. The hydrogel, derived from medical maggots, aims to promote wound healing through debridement and wound bed preparation. The publication marks a significant milestone for SolasCure as it progresses into further clinical studies.

March 04, 2024
4 Articles